Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Biological Chemistry

GSK Teams With Two Academic Centers

by Lisa M. Jarvis
December 17, 2012 | A version of this story appeared in Volume 90, Issue 51

GlaxoSmithKline has sealed two academic partnerships aimed at developing drugs against protein targets. GSK will work with Seattle-based Fred Hutchinson Cancer Research Center to develop a treatment that could reverse facioscapulohumeral muscular dystrophy (FSHD). The partners hope to discover a small molecule that can block the activity of a protein that is improperly expressed by the DUX4 gene in people with FSHD. And GSK will work with the University of Texas M. D. Anderson Cancer Center to develop antibodies that activate OX40, a receptor on the surface of T cells that enhances the immune system’s attack on cancer. M. D. Anderson could receive payments totaling $335 million.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.